Importance of early insulin secretion: Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

Diabetes Care

Volumn 24, Issue 6, 2001, Pages 983-988

  Hollander, Priscilla A ^a,d   Schwartz, Sherwyn L ^b   Gatlin, Marjorie R ^c   Haas, Stephen J ^c   Zheng, Hongjie ^c   Foley, James E ^c   Dunning, Beth E ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Diabetes and Glandular Disease Clinic   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; GLIBENCLAMIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN; NATEGLINIDE; PHENYLALANINE; PLACEBO; PROINSULIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC DIET; DIET RESTRICTION; DIET THERAPY; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SECRETION; SINGLE BLIND PROCEDURE; TIME;

AGED; AREA UNDER CURVE; BLOOD GLUCOSE; C-PEPTIDE; CYCLOHEXANES; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DOUBLE-BLIND METHOD; FASTING; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PHENYLALANINE; PLACEBOS; POSTPRANDIAL PERIOD; PROINSULIN; SINGLE-BLIND METHOD; TIME FACTORS;

EID: 0035374581     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.6.983     Document Type: Article

References (18)

1. Lebovitz HE: Insulin secretagogues: old and new. Diabetes Rev 7:139-153, 1999
2. Kelly D: Approaches to preventing prandial hyperglycemia excursions. Curr Opin Endocrinol Diabetes 6:S7-S11, 1999
3. Jeng C-Y, Hollenbeck CB, Wu MS, Chen YD, Reaven GM: How does glibenclamide lower plasma glucose concentrations in patients with type 2 diabetes? Diabet Med 6:303-308, 1989
4. Rosenstock J, Samols E, Muchmore DB, Schneider J, and The Glimepiride Study Group: Glimepiride, a new once-daily sulfonylurea. Diabetes Care 19:1194-1199, 1996
5. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
6. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
7. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes. Lancet 352:854-865, 1998
8. Mahler RJ, Adler ML: Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 84:1165-1171, 1999
9. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secre-tory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
10. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D Jr: Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229, 1976
11. Calles-Escandon J, Robbins DC: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 36:1167-1172, 1987
12. Leclercq-Meyer V, Ladriere L, Fuhlendorff J, Malaisse WJ: Stimulation of insulin and somatostatin release by two meglitinide analogs. Endocr J 7:311-317, 1997
13. de Souza CJ, Russo P, Lozito R, Dunning BE: Differential effects of short and long duration insulinotropic agents on mealrelated glucose excursions. Diabetes Obes Metab 3:73-83, 2001
14. Hanefeld M, Dickinson S, Bouter KP, Gui-tard C: Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 23:202-207, 2000
15. Dunning BE, Foley JE: New therapies to increase insulin secretion. In Diabetes Mellitus, A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins, 2000, p. 836-842
16. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD: Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes 47:523-529, 1998
17. Bergman RN: New concepts in extracellular signaling for insulin action: the single gateway hypothesis. Recent Prog Horm Res 52:359-387, 1997
18. Horton E, Clinkingbeard C, Gatlin M, Foley J: Nateglinide alone and in combination with Metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660-1665, 2000